Skip to main content
. 2012 Jan;5(1):23–30. doi: 10.1177/1756283X11423706

Table 1.

Main results of the three pivotal trials of prucalopride in gastrointestinal chronic constipation.

Reference Study design (No. of patients) Outcomes (2 mg and 4 mg prucalopride versus placebo)
[Camilleri et al. 2008b] 12 weeks (620) No. of patients achieving
Prucalopride 2 mg or 4 mg dailyversus placebo

  1. ≥3 SCBMs/week: 30.9% and 28.4% versus 12%

  2. An increase of ≥1 SCBM/week: 47.3% and 46.6%versus 25.8%
[Quigley et al. 2009] 12 weeks (641) No. of patients achieving:
Prucalopride 2 mg or 4 mgdaily versus placebo

  1. ≥3 SCBMs/week: 23.9% and 23.5% versus 12.1%

  2. An increase of ≥1 SCBM/week: 42.6% and 46.6%versus 27.5%
[Tack et al. 2009] 12 weeks (713) No. of patients achieving:
Prucalopride 2 mg or 4 mgdaily versus placebo

  1. ≥3 SCBMs/week: 19.5% and 23.6% versus 9.6%

  2. An increase of ≥1 SCBM/week: 38.1% and 44.1%versus 20.9%

SCBM, spontaneous complete bowel movement.